SBMF Online Payment ▶

test directorySearch Results

Click here to search again.

Test Name:
Platelet Function Inhibition - P2Y12


  • SBMF No:
    25053
  • Performance Lab Name:
    Hematology
  • Test Mnemonic:
    PLT P2Y12
  • ABN:
    Not required
  • CPT Code:
    85576x2
  • LOINC Code:
    49010-2; 49010-2; 5992-3
  • Also Known As:
    P2Y12 Inhibitors
    Plavix® (clopidogrel)
    Ticlid® (ticlopidinel)
    Feffient™ (prasugrel)
  • Spec Type:
    Whole blood
  • Spec Container:
    Special light blue top citrate tube (2.0 mL Greiner brand "reduced volume" tube with 3.2% sodium citrate)
      NOTE: Order SBMF #11460 to recieve special collection tubes for this test
  • Pref Vol:
    2.0 mL
  • Fasting:
    No
  • Spec Collect:
    Collect blood samples using a 21 gauge or larger needle
    First, collect 1.0 to 2.0 mL blood into a "discard" tube
      NOTE: Tube collected before test sample must never contain a platelet inhibiting substance (e.g., EDTA)
    Next, fill a second Greiner brand 2.0 mL citrate tube to volume indicated by black line on tube label (vacuum draw is 2.0 mL which is approximately half of tube capacity)
    Gently invert tube at least 5 times to ensure complete mixing of blood and anticoagulant
    Samples obtained from an indwelling catheter should be collected after sufficient discard, about 5.0 mL, has been drawn off to clear the line; ensure catheter is free of clots
    Samples obtained using a syringe must be immediately transferred to appropriate collection tube
  • Spec Process:
    Do not centrifuge
    Do not remove plasma from cells
    Do not refrigerate or freeze
  • Spec Store Transport:
    Room temperature
    Immediately transport sample to testing site – must arrive in SBMF coagulation lab within 4 hours of collection
    Do not transport via pneumatic tube system
  • Spec Stability:
    4 hours room temperature (20-30°C)
  • Spec Reject:
    Sample collected in tube other than 2.0 mL light blue top Greiner Vacuette® 3.2% sodium citrate tube
    Sample recieved more than 4 hours after collection
    Sample centrifuged, refrigerated or frozen
    Sample clotted or contains clots
  • Methodology:
    Turbidimetric Based Optical Detection
  • Use:
    Measure of effectiveness of platelet inhibition by P2Y12 receptor blockade drugs
  • Clinical Significance:
    The assay is designed to measure platelet P2Y12 receptor blockade. Substances known to specifically block the P2Y12 receptor include the thienopyridine class of drugs, including clopidogrel (Plavix®); Ticlid® (ticlopidine); Feffient™ (prasugrel).
    Three results will be reported for each assay:
     1.  P2Y12 Reaction Units (PRU) report the amount of P2Y12 receptor mediated aggregation
     2.  Baseline Result: The baseline aggregation result is reported from the TRAP-activated channel which is insensitive to the presence of a P2Y12 inhibitor
     3.  Inhibition (%) is the percent change from baseline aggregation, and is calculated from the PRU result and the BASE result
  • Reference Range:

    Pre-treatment/Baseline:
    194-418 PRU

    Therapeutic Treatment:
    Results greater than 235 PRU may indicate inadequate platelet inhibition, which is associated with increased risk of cardiovascular deaths, MI and stent thromboses.

    P2Y12 platelet inhibition is expected to be greater than 50%

    Note:
    Results are reported in P2Y12 Reaction Units (PRU)

  • Day Run:
    Sun-Sat (daily)
  • Time Run:
    As received
  • Time Reported:
    4 hours
  • Test Type:
    COAGULATION

Home > Test Directory > Search Results

Test Directory